menu search

PRME / Prime Medicine: Not Yet Primed For Retail Investment

Prime Medicine: Not Yet Primed For Retail Investment
Prime Medicine is developing prime editing, a highly precise gene editing technology that offers advantages over traditional CRISPR-Cas9 gene editing. Prime editing has shown promising results in human cell lines, including correcting genetic causes of diseases. The company's lead program is focused on Chronic Granulomatous Disease (CGD), a rare genetic disorder that affects the immune system. Read More
Posted: Sep 27 2023, 08:49
Author Name: Seeking Alpha
Views: 111774

PRME News  

Prime Medicine: Not Yet Primed For Retail Investment

By Seeking Alpha
September 27, 2023

Prime Medicine: Not Yet Primed For Retail Investment

Prime Medicine is developing prime editing, a highly precise gene editing technology that offers advantages over traditional CRISPR-Cas9 gene editing. more_horizontal

Prime Medicine: Gene Editing Tech With Unique Approach

By Seeking Alpha
April 23, 2023

Prime Medicine: Gene Editing Tech With Unique Approach

Prime Medicine: Gene Editing Tech With Unique Approach. more_horizontal

Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics

By Seeking Alpha
January 12, 2023

Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics

CRISPR Therapeutics is probably the most widely-known company utilizing the original CRISPR-Cas9 gene editing method. Prime editing is a newer variati more_horizontal


Search within

Pages Search Results: